TransMedics Group, Inc.

Equities

TMDX

US89377M1099

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
84.16 USD -3.53% Intraday chart for TransMedics Group, Inc. -8.34% +6.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $1,110,150, According to a Recent SEC Filing MT
Piper Sandler Initiates TransMedics Group With Overweight Rating, $95 Price Target MT
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating MT
Top Premarket Gainers MT
Transcript : TransMedics Group, Inc., Q4 2023 Earnings Call, Feb 26, 2024
TransMedics Group Swings to Net Income in Q4, Revenue Increases; Sets 2024 Revenue Outlook-- Shares Rise MT
TransMedics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TransMedics Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (TMDX) TRANSMEDICS GROUP Posts Q4 Revenue $81.2M, vs. Street Est of $68.5M MT
Transmedics Group, Inc. Provides Revenue Guidance for the Full-Year 2024 CI
Transmedics Group Insider Sold Shares Worth $279,720, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $344,432, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $1,281,750, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $804,088, According to a Recent SEC Filing MT
Transcript : TransMedics Group, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:00 PM
Transmedics Group Insider Sold Shares Worth $309,562, According to a Recent SEC Filing MT
Morgan Stanley Adjusts TransMedics Group Price Target to $75 From $54, Maintains Equal Weight Rating MT
Transmedics Group Insider Sold Shares Worth $701,400, According to a Recent SEC Filing MT
TransMedics Group, Inc. Enters Third Amendment to the Credit Agreement CI
TransMedics Group CEO Sold Shares Worth $964,800, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Top Midday Gainers MT
Morgan Stanley Adjusts Price Target on TransMedics to $54 From $50, Maintains Equal-Weight Rating MT
Chart TransMedics Group, Inc.
More charts
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
87.24 USD
Average target price
100.3 USD
Spread / Average Target
+15.01%
Consensus
  1. Stock Market
  2. Equities
  3. TMDX Stock
  4. News TransMedics Group, Inc.
  5. TransMedics : Shares Halted, News Pending